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Further to define the epitopes of PDC-E2, the major autoantigen in 
primary biliary cirrhosis (PBC), we have developed and characterized five 
human monoclonal antibodies. These antibodies were derived by fusing a 
regional hepatic lymph node from a patient with PBC with the mouse 
human heterohybrid cell line F3B6. Previous studies of epitope mapping 
ofPDC-E2 have relied on whole sera and have suggested that the immuno-
dominant epitope lies within the inner lipoyl domain of the molecule. 
However, selective absorption studies using whole sera and a series of over-
lapping recombinant peptides of PDC-E2 have suggested that the epitope 
may also include a large conformational component. Moreover, several 
laboratories have suggested that autoantibodies against the 2-oxo acids 
dehydrogenase autoantigens are cross-reactive. The five Inonoclonal anti-
bodies generated included three IgG2a and two IgM antibodies and were 
studied for antigen specificity using recombinant PDC-E2, recombinant 
BCKD-E2, histone, dsDNA, IgG (Fe), collagen and a recombinant irrele-
vant liver specific control, the F alloantigen. The antibodies were also used 
to probe blots of human, bovine, mouse and rat mitochondria. Finally, fine 
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specificity was studied by selective ELISA and absorption against over-
lapping expressing fragments ofPOC-E2. All five monoclonals, but none of 
the other mitochondrial auto antigens were specific for POC-E2. In fact, 
although affinity purified antibodies to POC-E2 from patients with PBC 
cross-reacted with protein X, the human monoclonals did not, suggesting 
that protein X contains an epitope distinct from that found on POC-E2. 
Additionally, all three IgG2 monoclonals recognized distinct epitopes 
within the inner lipoyl domain ofPOC-E2. 
Introduction 
Although the etiology of PBC remains enigmatic [1], antimitochondrial auto-
antibodies (AMA) from patients with PBC react with components of the 2-oxo acids 
dehydrogenase pathway, i.e., the E2 subunit of the pyruvate dehydrogenase complex 
(PDC-E2), the E2 subunit of the branched chain a-keto acid dehydrogenase 
complex (BCKD-E2), the E2 subunit of2-oxo-glutarate acid dehydrogenase complex 
(OGDC-E2); protein X and the Ela and El P subunits of pyruvate dehydrogenase 
complex [2-7]. Among these autoantigens, human PDC-E2 has been cloned, 
sequenced and expressed [8, 9]. Previous studies of epitope mapping have relied on 
whole sera and have suggested that the immunodominant epitope lies within the 
inner lipoyl domain of the molecule and may include a large conformational 
component [9, 10]. Additionally, several laboratories have proposed that AMA 
against the 2-oxo acid dehydrogenase auto antigens are cross-reactive [11-14]. These 
issues have also been studied with mouse monoclonal antibodies to PDC-E2; how-
ever, murine antibodies are not true antibodies and map to a different region 
of PDC-E2 than human patients with PBC [15]. Because of these problems, we 
have developed and report herein the characterization of five human monoclonal 
antibodies against PDC-E2. The availability of these reagents provides a valuable 
tool to address the fine specificity of antigenic epitopes in patients with PBe. 
Methods and materials 
Generation of hybridomas 
A regional lymph node from a patient with end-stage and well-established PBC was 
removed during liver transplantation. The serum from this patient was known to 
contain antimitochondrial antibodies to PDC-E2, BCKD-E2, PDC-Ela, protein X 
and OGDC by a combination of immunoblotting and ELISA assays [16-17]. In 
addition, a control normal lymph node was studied in parallel (see below). The 
resected lymph node was teased with forceps and scissors in Hanks' balanced salt 
solution (HESS) without calcium and magnesium. It was then passed through a 
22 gauge nylon mesh to prepare a single cell suspension at 5 x 106 cells/ml. A similar 
single cell suspension was prepared from normal human lymph node cells, removed 
during a diagnostic laparotomy. The fusion partner used was the mouse-human 
heterohybrid cell line F3B6. 
F3B6, which is known to be 6-thioguanine- and ouabain-resistant, was produced 
by fusing NS-l mouse myeloma cells with human peripheral blood lymphocytes. 
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Previously, hybridomas produced with this fusion partner have been shown to 
produce human Ig in the range of 1-50 tJg/ml [18, 19]. The optimal ratio for fusions 
was established in pilot experiments using regional lymph nodes and peripheral 
blood from several other patients. The lymph node cells were washed in HBSS 
without calcium and with 2 mM magnesium (HBSS ±). F3B6 was washed separately 
inHBSS ±. Thence,S x 106 lymph node cells were mixed with 5 x 106 F3B6 cells and 
the total cells added to a Falcon 6-well plate which had been previously treated with 
5 mg/ml peanut agglutinin at 37°C. After centrifuging at 500 x g for 6 min at room 
temperature, the supernatant was aspirated off and 2 ml of prewarmed (3TC) 40°;, 
PEG fusion mixture (8 g PEG 4000,2 ml DMSO to 20 ml HBSS ±) added down the 
side ofthe wells. One min later, 4 ml of warm HBSS ± with 5% DMSO (FDM) was 
added slowly, followed by 4 ml of FDM. The wells were then aspirated and an 
additional 2 ml of FDM added. The wells were then washed with HBSS ± and the 
plates centrifuged at 400 x g for 5 min. The supernatants were then removed and the 
monolayer washed by the addition of 2 ml of HBSS ± followed by centrifugation at 
400 xg for 5 min. After a final aspiration, 3 ml of growth medium (GM-Iscoves' 
Modified Dulbecco's medium supplemented with 10% prescreened heat inactivated 
fetal bovine serum,S x 10- 3 IU/ml bovine insulin,S tJg/ml human transferrin, 
5 ng/ml sodium selenite,S tJg/ml human low density lipoprotein, 50 IU /ml penicillin 
and 50 tJg/ml streptomycin) was added. The plates were incubated overnight at 3TC 
in a 7% CO2 incubator. The fused cells were then diluted with GM containing 
100 JlM hypoxanthine (HA) and seeded into 96-well flat-bottom plates at a density 
of 1 x 105 cells/well; the cells were fed HAGM every third day. The hybrids 
were assayed for antibodies to PDC-E2 by ELISA, beginning on the 14th day. 
Positive wells were sub cloned with two rounds of limiting dilution. Wells were 
screened microscopically daily and only wells containing one colony were regarded as 
monoclonal. 
Antigens 
PDC-E2 were purified from bovine kidney as described [20]. Human PDC-E2 
and bovine BCKD-E2 were cloned respectively into the expression plasmids 
PUR [9, 21] and pKK233-2 [22,23]. E. coli transfoqned with an expression plasmid 
of human PDC-E2 [9] or bovine BCKD-E2 [22,23] were grown overnight in L-broth 
with 25 Jlg/ml ampicillin at 37°C. The overnight cultures were then diluted 1: 10, 
incubated at 37°C for 1 h and induced with 1 mM isopropyl thiogalactosidase (IPTG) 
for 3 h at 37°C. The cells were harvested and lysed by sonication. The lysate was 
resolved by SDS-PAGE stained with Coomassie blue, and the percentage of 
recombinant protein in the lysate was determined [24]. Typically, recombinant 
PDC-E2 and BCKD-E2 represent 10-15 % of the total protein. Mouse histones were 
a gift of Drs Peter Yau and Morton Bradbury of the Department of Biological 
Chemistry at the University of California, Davis. They were prepared by 0.4 N H 2S04 
extraction of nuclei from mouse EL-4 thymoma cells. DNA was removed by 
centrifugation and the solubilized histones dialysed extensively against water and 
lyophilized. Double stranded DNA was prepared by extracting calf thymus DNA 
(Sigma Chemical Co., St. Louis, MO, USA) with phenol/chloroform. The DNA 
were then precipitated in ethanol, resuspended at 0.5 mg/ml in PBS and stored 
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frozen in small aliquots. IgG (Fc) (Jackson ImmunoResearch, West Grove, PA, 
USA) was dissolved in carbonate buffer at 10 )lg/ml. Collagen (Eureka Laboratories, 
Sacramento, CA, USA) was solubilized in acetic acid and then resuspended at 
10 )lg/ml in carbonate buffer pH 9.6. The recombinant liver specific F alloantigen 
was prepared as described [25]. The F antigen served as both an additional antigen 
control and as a recombinant control. 
Screening of monoclonals 
Supernatants were initially screened with native PDC-E2 as previously 
described [17]. Known positive and negative sera were used throughout as quality 
controls. Since there were no differences in using native or recombinant PDC-E2 in 
the screening procedure, subsequent ELISA were performed using recombinant 
PDC-E2. To determine the class and subclass specificities of the monoclonal 
antibodies, the monoclonal antibodies were probed with optimal dilutions of mouse 
monoclonal anti-human )l. y. (1, IgGl, IgG2, IgG3, IgG4, K and A chains (Caltag 
Laboratories, South San Francisco, CA, USA) with known positive and negative 
reagents. Goat anti-mouse heavy and light chain antibodies were also used 
throughout to confirm the absence of mouse antibodies in the monoclonal 
supernatants. 
Specificity 
Antigen specificity was first studied by ELISA using recombinant human 
PDC-E2 [9], recombinant bovine BCKD-E2 [22,23], histone, dsDNA, IgG (Fc), 
collagen and a recombinant irrelevant liver specific control, the F antigen [25] 
at 10 )lgjml. After blocking, 100)l1 of monoclonal supernatant was added and 
incubated at room temperature for 2 h and washed three times with PBS containing 
0.05% Tween 20. The wells were then incubated with peroxidase conjugated 
anti-human Ig (Tago, Burlingame, CA, USA) at a predetermined optimal dilution 
of 1 :3,000. After 1 h incubation at room temperature, the wells were washed three 
times with PBS Tween and the color developed by incubating with 2,2' -azino-bis 
(3-ethylbenzthiazoline-6-sulfonic acid) [22]. The reaction was stopped by adding 
100)l1 of 5% SDS after an additional 10 min and the results were recorded at 
495nm. 
Following ELISA, all reagents specific for PDC-E2 were further studied by 
immunoblotting against mammalian mitochondria. Mitochondrial preparations 
from human placenta, bovine heart, and mouse and rat liver were prepared as 
described [15]. The samples were boiled in SDS sample buffer before loading onto 
10% SDS-polyacrylamide gel at 10)lg protein per lane. The resolved proteins were 
then transferred to nitrocellulose filters and probed with human monoclonals, 
PBC sera (1:1,000 dilution) and sera from healthy volunteers as described [10]. 
Immunoreactivity was detected using 1125 anti-human Ig (Amersham, Arlington 
Heights, IL, USA) and autoradiography. Since protein X is abundant in bovine 
mitochondrial preparations, immunoreactivity against protein X was scored from 
the bovine heart mitochondrial blot [13]. 
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In both the ELI SA and the immunoblotting assays, human sera from patients with 
PBC with known reactivities to PDC-E2, BCKD-E2, OGDC-E2, PDC-Ela and 
protein X were used throughout as controls. 
Fine specificity against the PDC-E2 domain 
A series of overlapping expressing clones of PDC-E2 were generated as described 
[9]. Firstly, an EcoRI fragment (nucleotide 745-2536) of the human clone encoding 
the entire mature PDC-E2, including 16 residues of the leader sequence, was ligated 
into the frame-matched plasmid pUR [21]. The fusion protein expressed from the 
plasmid was purified in the presence of a reducing agent and SDS. The reducing 
agent and SDS were removed by gel filtration chromatography. Fractions containing 
the recombinant proteins were pooled and concentrated. To localize the antigenic 
determinants on human PDC-E2, restriction fragments encoding most or all of each 
domain were generated and fusion proteins expressed. Briefly, individual aliquots 
of the large EcoRI partial fragment were digested with DraI and the resulting 
fragments subcloned into frame-matched derivatives of pUR. The second DraI 
fragment encoding the inner lipoyl domain was further digested with either Alul, 
RsaI or Ncol, and the resulting partial or fully digested fragments subcloned. 
These plasmids were used to transform E. coli JM101 cells and the fusion protein 
induced with 10 mM IPTG. As noted above, an irrelevant control, a cDNA fragment 
encoding the rat liver specific F alloantigen [25] was ligated into the same vector and 
utilized throughout. 
These expressing sub clones were studied by immunoblotting. The clones were 
induced with IPTG and lysates transferred onto nitrocellulose paper as 
described [9, 20]. The transferred protein was incubated with supernatants of the 
human monoclonals for 2 h at room temperature, washed three times with PBS 
Tween and incubated with 1125 anti-human Ig (Amersham) for 1 h at room 
temperature and thereafter washed with PBS Tween as before. The blot was then 
incubated overnight on X-ray film. Known positive and negative sera were used 
throughout these studies. 
Finally, these overlapping expressing clones were also studied by selective 
absorption. The supernatants were absorbed with either the full length human 
PDC-E2 or with individual PDC-E2 subclones as described [9]. 
Briefly, overnight cultures of the PDC-E2 subclones were diluted 1:10 with 
L-broth and 25 Jlg/ml ampicillin, then induced with 1 mM IPTG for 6 h; cells were 
then harvested and lysed by sonication. The human monoclonals were incubated 
with 10 mg/ml sonicated extract at 4°C overnight and centrifuged at 10,000 x g for 
10 min to pellet the E. coli lysate. Monoclonals were also absorbed with the control 
plasmid as a control. The absorbed supernatants were then probed against the full 
length PDC-E2 by ELISA as described above. 
PDC inhibition assay 
The effects of human monoclonals on PDC enzyme actIvIty were studied by 
monitoring substrate-dependent NADH production [26]. Briefly, a predetermined 
optimal concentration of monoclonal was first incubated with purified PDC enzyme 
708 Patrick S. C. Leung et al. 
(Sigma Chemical Co., St. Louis, MO, USA) for 10 min at room temperature in 
0.1 ml of 0.3% BSA-PBS and then with 0.9 ml of reaction mixture. The reaction 
mixture contained 50 11M potassium phosphate, pH 8.0, 211M sodium pyruvate, 
2.5 11M NAD+, 0.2 11M thiamine pyrophosphate, 0.13 11M coenzyme A, 111M MgCl2 
and 0.3 11M dithiothreitol. The change in absorbance at 30°C was monitored at 
340 nm and compared with control enzyme complex without antibody. 
Results 
Generation and characterization of human monoclonals against PDC-E2 
Following fusion, hybridoma growth was observed in 25 of 500 culture wells; five of 
these wells were stable and produced antibody against PDC-E2. The antibodies 
include three IgG and two IgM monoclonals. Further characterization revealed that 
the three IgGs all belong to the IgG2 subclass, with two of them having A-light chain 
and one K-light chain. Both of the two IgM monoclonals were K-light chain. All five 
monoclonals were reactive with anti-human Ig but not to either goat anti-mouse 
heavy or light chains, indicating the absence of any murine antibodies. Finally, the 
fusion of B cells from lymph nodes of a non-PBC patient did not yield any PDC-E2 
specific human monoclonals. 
Antigen specificity of human monoclonals 
All five monoclonals reacted strongly and specifically to PDC-E2 but not to histone, 
dsDNA, human IgG (Fc) collagen, the liver specific F antigen [25] or recombinant 
BCKD-E2 using ELISA (Figure 1). The reactivity of these monoclonals was 
also tested by immunoblotting against beef heart mitochondria. The three IgG 
monoclonals were reactive only to PDC-E2, the 74 kDa mitochondrial antigen, 
but not to the other mitochondrial autoantigens, namely BCKD-E2, OGDC-E2, 
PDC-Ela or protein X (Figure 2). The two IgM monoclonals did not blot. 
Reactivity of human monoclonals against various mammalian species 
The monoclonal antibody reagents were compared by analysing reactivity against 
human, bovine, rat and mouse mitochondrial extracts (Table 1). PBC sera and the 
three IgG monoclonals reacted to the PDC-E2 from all species. However, reactivity 
to protein X was only observed in PBC sera and was not noted in any of the three 
human IgG monoclonals (Figure 2). 
Inhibition of PDC enzyme activity by human monoclonals 
PBC sera and the human monoclonals were able to inhibit PDC enzyme activity to a 
similar degree. For example, polys era from patients with PEC were able to inhibit 
enzyme activity to about 64%. Inhibition of PDC-E2 activity by the human 
monoclonals ranged from 74-79% (Table 1). Neither an irrelevant monoclonal 
control nor sera from normal volunteers demonstrated inhibition of enzyme activity. 
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Figure I. Antigen specificity of IgM and IgG secreting human monoclonals. Supernatants from human 
hybridoma were assayed for their reactivity against a panel of antigens by ELISA. The results were scored 
by measuring the optical densities of the individual wells. Note the high optical density (mean ± SEM) 
observed with PDC-E2 as antigen but not the other antigens, P<O.OI Student's t-test .• PDC-E2; 
e::::l histone; ds DNA; 1:\Sj IgG (Fc); II collagen; III F protein; ~ rBCKD-E2 
Immunoreactivity against the structural domains of PDC-E2 
Using expression clones of full length PDC-E2 (amino acid residues 1-560) and 
subc10nes containing the outer lipoyl domain (amino acid residues 1-96), the inner 
lipoyl domain (amino acid residues 91-227), the El/E3 binding site (amino acid 
residues 229-401) and the catalytic domain (amino acid residues 396-506) of human 
PDC-E2 [9], we addressed the issue of binding specificities by selective absorption. 
Immunoblotting results show that the incubation of the monoclonals with E. coli 
expression clones of full length PDC-E2 and the inner lipoyl domain removed 
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74 
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Figure 2. Beef heart mitochondria were separated by SDS-PAGE, blotted and probed with antisera. 
Lanes 1,2 and 3 correspond to the IgG monoclonals C6, CII and G2 respectively. Lane 4 has been probed 
with a known positive PBC serum control. Lane 5 has been probed with a normal human serum control. 
Note that the human monoclonals in lanes 1,2 and 3 react only to PDC-E2 and not to either protein X or 
BCKD-E2. In contrast, sera from the patient with PBC reactto the 74 kDa PDC-E2, the 55 kDa protein X 
and the 52 kDa BCKD-E2. This pattern of unique reactivity to only the 74 kDa antigen with the human 
monoclonals was also found even with more concentrated preparations of antibody (data not shown). 
Table 1. Immunological profiles of human IgG monoclonal antibodies* 
Immunoblottingt 
~~ Inhibition 
Antibodies Isotypes L chain Human Bovine Mouse Rat activityt Epitope§ 
C6 IgG2 A + + + + 74 128-227 
Cl1 IgG2 Ie + + + + 77 136-227 
G2 IgG2 1( + + + + 79 91-227 
Serall IgG2 A.K + + + + 64 91-227 
*PDC-E2 specific human monoclonal antibodies were generated by fusing B cells from the lymph node 
of PBC patient with the mouse-human heterohybrid cell line F3B6. 
tImmunoblotting was performed against purified mitochondria from human placenta, bovine heart, rat 
liver and mouse liver. 
tThe ability of monoclonal antibodies to inhibit PDC enzyme activity in vitro. Normal sera and 
irrelevant monoclonal antibody control do not inhibit. 
!iEpitopes are represented as amino acid residues of PDC-E2. All epitopes were localized to the inner 
lipoyl domain. 
II Sera from the same PBC patient from whom the monoclonal antibodies were derived. 
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180 
Figure 3. Lysates of E. coli containing the full length human PDC-E2 were separated by SDS-PAGE, 
blotted and probed with various preparations of monoclonal CII. The 180 kDa band is the recombinant 
fusion protein. The monoclonal antibodies used were initially absorbed with E. coli crude lysates contain-
ing expression clones of various domains of PDC-E2. The monoclonal CII was absorbed with the 
following: an irrelevant control plasmid (lane I); the full length PDC-E2 (lane 2); amino acids 1-96 (lane 
3); amino acid residues 91-227 (lane 4); amino acid residues 128-227 (lane 5); amino acid residues 136-227 
(lane 6); amino acid residues 146-227 (lane 7); amino acid residues 160-227 (lane 8); amino acid residues 
181-227 (lane 9); amino acid residues 229-401 (lane 10); amino acid residues 396-560 (lane II). Note the 
removal of reactivity by the full-length PDC-E2, amino acid residues 91-227 (lane 4), 128-227 (lane 5) and 
136-227 (lane 6). In contrast, control plasmid (lane I) and clones containing amino acid residues 1-96 (lane 
3), 146-227 (lane 7), 160-227 (lane 8),181-227 (lane 9), 229-401 (lane 10) and 396-560 (lane 11) do not 
absorb reactivity. A similar pattern was seen with the other IgG monoclonal reagents. 
immunoreactivity against the full length protein (Figure 3, lane 2 and 4). All three 
IgG human monoclonals reacted to the full length PDC-E2 and the inner lipoyl 
domain, but not to the outer lipoyl, the EI/E3 binding site or the catalytic domain of 
PDC-E2 (Table 2). 
Since the specific immunoreactivity of the IgG human monoclonals against the 
inner Jipoyl domain resembles the polyclonal sera reactivity of PBC patients, the fine 
reactivity of human monoclonals was further examined with an overlapping series of 
expression clones of the inner IipoyI domain of PDC-E2. Lysates of a series of 
overlapping expression clones of the PDC-E2 inner Jipoyl domain were incubated 
with human monoclonals and were then probed with an expression clone of full 
length PDC-E2. Although the three PDC-E2 specific IgG2 monoclonals were 
derived from the same patient, fine mapping of their specificities revealed 
differences. For example, the reactivity of monoclonal G2 was absorbed within 
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amino acid residues 91-227 and partially within amino acid residues 128-227. In 
contrast, expression clones containing amino acid residues 91-227, 128-227 and 
136-227 were all able to absorb immunoreactivity of monoclonal C11 to a similar 
degree, suggesting that the epitope of C11 maps within amino acid residues 136-227 
of PDC-E2. On the other hand, the immunoreactivity of monoclonal C6 was 
absorbed by amino acid residues 91-227 and 128-227 and partially even within 
amino acid residues 160-227 (Table 2). Plasmid control and the other clones bearing 
amino acid residues beyond that range showed negligible reactivity (Figures 3 and 4). 
When the same absorbed PBC sera were used to probe a full length expressing clone 
of human PDC-E2, similar results were observed (Table 2). Finally, it was not 
possible to map the two IgM monoclonals by ELISA (see Discussion). 
Discussion 
Several autoantigens have now been cloned and sequenced and their immuno-
dominant epitopes mapped by both human polysera and murine mono-
clonals [15, 27-30]. However, murine monoclonal antibodies to auto antigens 
have often been found to map to a different antigenic epitope than human auto-
antibodies [15,28]. In contrast, attempts to produce human monoclonal antibodies 
have often been hindered by the failure to develop immortalized human B cells. Most 
procedures require the transformation of peripheral B cells by Epstein-Barr virus 
prior to fusion [31, 32]. Herein we report the generation of three IgG and two IgM 
PDC-E2 specific human monoclonals using the mouse human heterohybrid F3B6. 
Although the predominant Ig of AMA from sera of PBC patients are IgM and 
IgG3 [33], the IgG subclass specificities seen in the serum samples from the patients 
studied herein was predominantly IgG2 (data not shown). Thus, the predominant 
IgG2 AMA from the patient was identical to the IgG2 subclass of the human mono-
clonals. This suggests that the antibodies that resulted from the fusion reflected 
either the in vivo regional lymph node of this patient or, alternatively, that starter 
fusion occurs only with IgG2-producing B cells. However, the mouse-human hetero-
hybrid line F3B6 has been previously shown to generate IgG3 and IgM mono-
clonals from rheumatoid synovial cells [34]. Thus, the observation that we developed 
only IgG2 monoclonals is unlikely owing to the limitations of the starter fusion. We 
should also note that our success is likely due to the large number of available B cells 
in lymph nodes in contrast to use of peripheral blood lymphocytes. The use ofF3B6 
also minimizes possible artefacts that might be induced by B cells that are activated or 
transformed by Epstein-Barr virus. 
Earlier studies have shown that the autoepitope of PDC-E2 is localized to the 
lipoyl domain of PDC-E2 [3,9, 11,35]. Van de Water et al. [3] have previously 
identified that a 20 amino acid peptide within the lipoyl domain was able to absorb the 
antibody reactivity from PBC sera against rat PDC-E2. Surh et at. [9] have suggested 
that a minimum stretch of92 amino acids (residues 136-227) within the inner lipoyl 
domain of human PDC-E2 is essential for antibody recognition and imply that a 
specific conformation is required. Similarly, several studies have also demonstrated 
that PBC sera react with the PDC-E2 component of E. coli [14, 35]. Using genetically 
engineered variants of the E. coli PDC-E2, Fussey et al. [14] reported that sera 
A
m
in
o 
ac
id
 
re
si
du
e 
C
on
tro
l 
1-
56
0 
1-
96
 
91
-2
27
 
12
8-
22
7 
13
6-
22
7 
14
6-
22
7 
16
0-
22
7 
18
1-
22
7 
22
9-
40
1 
39
6-
50
6 
T
ab
le
 2.
 R
ea
ct
iv
ity
 o
f P
B
G
 se
ra
 a
n
d 
hu
m
an
 m
o
n
o
c
lo
na
l a
n
tib
od
ie
s a
ga
in
st
 e
xp
re
ss
io
n 
clo
ne
s o
f h
um
an
 P
D
G
-E
2*
 
H
um
an
 m
o
n
o
c
lo
na
l a
n
tib
od
ie
s 
PB
C
 S
er
a 
C
6 
C1
1 
G
2 
M
ea
n 
R
an
ge
 
M
ea
n 
R
an
ge
 
M
ea
n 
R
an
ge
 
M
ea
n 
R
an
ge
 
0.
68
6 
+
 0
.0
25
 
0.
66
3-
0.
71
1 
0.
17
9 +
 0
.0
06
 
0.
17
4-
0.
18
3 
0.
56
7 
+
 0
.0
18
 
0.
54
1-
0.
58
5 
0.
27
8 
+
 0
.0
 
0.
27
8-
0.
27
8 
I 
0.
10
6+
0.
00
6 
0.
10
1-
0.
11
11
1 
0.
03
5+
0.
00
1 
0.
03
5-
0.
03
61
1 
0.
05
4+
0.
00
6 
0.
04
9-
0.
06
0 
II
 0
.0
59
+0
.0
04
 
0.
05
7-
0.
06
21
 
0.
54
5 
+
 0
.0
25
 
0.
51
2-
0.
57
3 
0.
20
3 
+
 0
.0
18
 
0.
19
0-
0.
21
5 
0.
55
2 
+
 0
.0
28
 
0.
52
3-
0.
58
8 
0.
33
9 
+
 0
.1
1 
0.
33
2-
0.
34
7 
I 
0.
15
9+
0.
01
0 
0.
14
7-
0.
17
0 
I 
0.
04
2±
0.
00
8 
0.
03
6-
0.
04
8 
0.
09
2±
0.
00
8 
0.
08
4-
0.
09
9 
I 
0.
06
2+
0.
00
2 
0.
06
H
).0
64
I 
0.
40
8 
±
 0
.Q
l9 
0.
39
0-
0.
43
5 
0.
03
3 
+
 0
.0
02
 
0.
03
2-
0.
03
5 
0.
08
2 
±
 0
.0
09
 
0.
07
4-
0.
09
0 
0.
21
9 
±
 0
.0
02
 
0.
21
7-
0.
22
0 
0.
42
5 
±
 0
.0
20
 
0.
40
6-
0.
44
9 
0.
12
7 
±
 0
.0
01
 
0.
12
6-
0.
12
8 
0.
11
1 
+
 0
.Q
l5 
0.
09
7-
0.
12
8 
0.
30
7 
±
 0
.0
 
0.
30
7-
0.
30
7 
0.
50
9±
0.
02
3 
0.
48
1-
0.
53
4 
0.
12
6±
0.
01
4 
0.
11
6-
0.
13
6 
0.
54
2±
0.
00
5 
0.
53
6-
0.
54
6 
0.
28
1±
0.
01
8 
0.
26
8-
0.
29
3 
0.
48
9±
0.
02
0 
0.
46
1-
0.
50
6 
0.
11
1 
±
0.
00
6 
0.
10
7-
0.
11
3 
0.
54
2±
0.
03
4 
0.
50
4-
0.
57
0 
0.
30
2±
0.
00
4 
0.
29
9-
0.
30
4 
0.
58
9±
0.
05
1 
0.
52
9-
0.
65
2 
0.
19
3±
0.
02
8 
0.
17
3-
0.
21
3 
0.
56
0±
0.
02
3 
0.
53
6-
0.
57
9 
0.
27
4±
0.
00
1 
0.
27
3-
0.
27
4 
0.
49
5±
0.
01
7 
0.
47
1-
0.
50
7 
0.
18
6±
0.
01
6 
0.
17
5-
0.
19
7 
0.
55
3±
0.
02
2 
0.
53
3-
0.
57
2.
 
0.
32
4±
0.
01
3 
0.
31
4-
0.
33
3 
0.
59
3 
±
 0
.0
34
 
0.
54
9-
0.
62
7 
0.
18
9 ±
 0
.0
07
 
0.
18
4-
0.
19
4 
0.
54
4 ±
0.
01
4 
0.
52
7-
0.
55
5 
0.
32
6 
±
 0
.0
 
0.
32
6-
0.
32
6 
*
A
bs
or
pt
io
n 
st
ud
ie
s 
sh
ow
 th
at
 e
x
pr
es
si
on
 c
lo
ne
s o
f e
ith
er
 fu
ll 
le
ng
th
 P
D
C
-E
2 
(re
sid
ue
 1
-5
60
) o
r 
su
bc
lo
ne
s 
c
o
n
ta
in
in
g 
a
m
in
o 
a
c
id
 re
si
du
es
 9
1-
22
7,
 1
28
-2
27
 a
n
d 
13
6-
22
7 
c
a
n
 r
e
du
ce
 im
m
un
or
ea
ct
iv
ity
 o
f t
he
 P
B
C
 se
ra
 a
n
d 
th
e 
hu
m
an
 m
o
n
o
c
lo
na
ls
 to
 v
a
ri
ou
s d
eg
re
es
. 
=
: a III ::s 51 o ::s o (') -o ~ ~ ... ... c:r o Co ... ~ <Ii ... o ~ ~ I ~ ...;j -~ 
714 Patrick S. C. Leung et al. 
Inner Llpoyl Domain (128·229) 
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FigUre 4. A schematic representation of the reactivity of PBC sera and C6, C11 and G2 monoclonal 
antibodies against expression cDNA clones of human PDC-E2. Note the specific reactivity against the 
inner lipoyl domain and within amino acid residues 91-227, 128-227, 136-227 of the inner lipoyl domain. 
Other expression clones do not react. (+) Positive reactivity; (-) negative reactivity; (*) partial 
reactivity. Data compared with the control value of the full length PDC-E2 (Table 2) and for each 
monoclonal respectively. 
of PBC patients recognized the lipoyl domain of E. coli PDC-E2 as the immuno-
dominant region. Moreover, substitution of lipoic acid by octanoic acid mimics the 
unique peptide-cofactor' conformation, suggesting that both the lipoyl moiety and 
the peptide backbone are the major integral part of the B-cell epitope. In contrast, 
removal of lipoic acid by site directed mutagenesis of the lysine residue within a 413 
base pair eDNA clone encoding the inner lipoyl domain of the human PDC-E2 did 
not affect antibody recognition by PBC sera [36]. Thus, the role of lipoic acid as an 
epitope is still unclear. Finally, a recent study took advantage of the ability of PBC 
sera to inhibit the in vitro catalytic function of the PDC enzyme and reported the 
presence of a population of non-blotting, but enzyme inhibiting autoantibodies in 
PBC. These were interpreted as indirect evidence for reactivity to a conformational 
determinant [37]. 
Epitope mapping with the IgM monoclonals was not possible owing to their 
inability to blot and their multiple reactivity to various expression clones of the 
PDC-E2 structural domains by ELISA. We believe that the main difficulties of 
. studying IgM lie in the oligomeric structure and the stickiness of IgM which results 
in a heteroclitic response. Nevertheless, the selective absorption of anti-PDC-E2 
reactivities by a number of overlapping subclones of PDC-E2 and the fact that a 
minimum stretch of 92 amino acid residues is required for the three IgG human 
monoclonals (Table 2, Figure 4) strongly indicates the presence of conformational 
epitope(s). 
The presence of conformational epitopes in PDC-E2 can be discussed with respect 
to other autoantigens. For example, the histidy t-RNA transferase of myositis-
associated anti-Jo-l autoimmune response [30] contains both conformational and 
multiple linear epitopes. Multiple epitopes, including linear and discontinuous 
epitopes, have also been mapped in p70 [38, 39] in systemic lupus erythematosus 
(SLE). The U SnRNP associated BIB polypeptide of SM autoantibodies in SLE [40] 
has six epitopes, some of which are conformational. In some autoantigens, such 
as Sm BIB, a repeated proline rich motif PPGMRPP is the dominant epitope 
recognized by both human and murine antibodies [41]. In the case of the La antigen 
of Sjogren's syndrome, three distinct epitopes, LaA, LaC and LaL2/3, have been 
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identified. The LaA contains the first 107 amino acid residues from the N-terminal, 
the LaC contains amino acid residues 111-242, which is comprised of a RNA 
consensus sequence and helical core, and LaL2/3 constitutes amino acid residues 
346-408, which contains a linear epitope [29,42]. Evidently, therefore, both linear 
and conformational epitopes are common among autoantigens. 
The PDC-E2-specific human IgG2 monoclonal antibodies reported herein inhibit 
PDC enzyme activity in vitro. This is similar to PBC polysera [43-46]. The ability of 
autoantibodies to inhibit enzyme function has also been demonstrated in other 
autoimmune diseases. For example, such data include the inhibition of t-RNA 
aminoacylation by autoantibodies to t-RNA synthetases in polymyositis sera [47] 
and inhibition of thyroid peroxidase activity by thyroid microsomal antibody [48]. 
Moreover, antibodies to the proliferating cell nuclear antigen in SLE have been 
reported to inhibit DNA replication in vitro [49] and RNA polymerase I specific 
antibodies from scleroderma sera inhibit the synthesis of28S and 18S RNA [50]. The 
inhibition of enzyme activity by autoantibodies suggests that these autoantibodies 
are most likely to be directed against the functional sites of the enzyme. However, the 
functional significance of enzyme inhibition by autoantibodies and their possible role 
in disease development are unclear. Finally, it is believed that antigens recognized by 
IgG2 are primarily carbohydrate in nature. In contrast, PDC-E2 is devoid of carbo-
hydrate moieties. Clearly, more work on the genetic origin of clones reported herein 
and on similarly derived hybridomas from other patients is needed for continued 
investigation of the fundamental questions regarding autoantibody formation and 
pathogenic significance. 
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